Inhibition of and sensitization to the lethal effects of tumor necrosis factor

Journal of Inflammation

Volumn 47, Issue 1-2, 1995, Pages 18-26

  Brouckaert, Peter ^a   Libert, Claude ^a   Cauwels, Anje ^a   Everaerdt, Bart ^a   Van Molle, Wim ^a   Ameloot, Paul ^a   Gansemans, Yannick ^a   Grijalba, Bernardo ^a   Takahashi, Nozomi ^a   Truong, Marie José ^a   Van Leuven, Peter ^a   Fiers, Walter ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

1 acid glycoprotein; 1 antitrypsin; acute phase proteins; Bacillus Calmette Guerin; interferon ; interferon ; interleukin 12; nitric oxide, methylene blue; platelet activating factor

Indexed keywords

TUMOR NECROSIS FACTOR;

CANCER; CANCER IMMUNOLOGY; CONFERENCE PAPER; HUMAN; HYPOTENSION; INFECTION; LIVER FAILURE; PRIORITY JOURNAL; SENSITIZATION; SHOCK;

ANIMALS; COMMUNICABLE DISEASES; CYTOKINES; DRUG INTERACTIONS; HUMANS; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029553848     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Fiers W: Biologie therapy with TNF: Preclinical studies. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): "Bio-logic Therapy of Cancer. 2nd Ed." Philadelphia: J.B. Lippincott, 1995, pp 295-327.
2. Lejeune F, Liénard D, Eggermont A, Schraffordt Koops H, Kroon B, Gérain J, Rosenkaimer F, Schmilz P: Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 43:191-197, 1994.
3. Fraker DL, Alexander HR, Pass HI: Biologic therapy with TNF: Systemic administration and isolation-perfusion. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): "Biologic Therapy of Cancer. 2nd Ed." Philadelphia: J.B. Lippincott, 1995, pp 329-345.
4. Takahashi N, Brouckaert P, Fiers W: Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice. Cancer Res 51:2366-2372, 1991.
5. Takahashi N, Fiers W, Brouckaert P: Anti-tumor activity of tumor necrosis factor in combination with interferonY is not affected by prior tolerization. Int J Cancer 63:846-854, 1995.
6. Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brouckaert P, Fiers W: Human TNF mutants with selective activity on the p55 receptor. Nature 361:266-269, 1993.
7. Brouckaert P, Ameloot P, Cauwels A, Everaerdt B, Libert C, Takahashi N, Van Molle W, Fiers W: Receptorselective mutants of tumour necrosis factor in the therapy of cancer: Preclinical studies. Circ Shock 43:185190, 1994.
8. Brouckaert P, Libert C, Everaerdt B, Fiers W: Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 11:193-196, 1992.
9. Lehmann V, Freudenberg MA, Galanos C: Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 165:657-663, 1987.
10. Brouckaert P, Everaerdt B, Fiers W: The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Eur J Immunol 22:981986, 1992.
11. Rothstein JL, Schreiber H: Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sei USA 85:607-611, 1988.
12. Libert C, Van Bladel S, Brouckaert P, Shaw A, Fiers W: Involvement of the liver, but not of IL-6, in IL-1induced desensitization to the lethal effects of tumor necrosis factor. J Immunol 146:2625-2632, 1991.
13. Everaerdt B, Brouckaert P, Shaw A, Fiers W: Four different interleukin-1 species sensitize to the lethal ac-tion of tumour necrosis factor. Biochem Biophys Res Commun 163:378-385, 1989.
14. Bartholeyns J, Freudenberg M, Galanos C: Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor. Infect Immun 55:2230-2233, 1987.
15. Cauwels A, Brouckaert P, Grooten J, Huang S, Aguet M, Fiers W: Involvement of IFN-yin Bacillus CalmetteGuérin-induced but not in tumor-induced sensitization to TNF-induced lethality. J Immunol 154:2753-2763, 1995.
16. Cauwels A, Fiers W, Brouckaert P: Murine IL-12 is involved in Calmette-Guérin bacillus-induced sensitization and is by itself sufficient to sensitize mice to the lethal effects of human TNF. J Immunol 156:4686-4690, 1996.
17. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF: NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sei USA 87:3629-3632, 1990.
18. Shultz PJ, Raij L: Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 90:1718-1725, 1992.
19. Kubes P, Suzuki M, Granger ON: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sei USA 88:4651-4655, 1991.
20. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M: The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 180:1153-1158, 1994.
21. Griffiths MJD, Curzen NP, Sair M, Evans TW: Nitric oxide synthase inhibitors in septic shock: Theoretical considerations. Clin Intens Care 5:29-36, 1994.
22. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ, Ignarro LJ: Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: Effects of méthylène blue and methemoglobin. J Pharmacol Exp Ther 219:181-186, 1981.
23. Preiser JC, Zhang H, Vincent JL: Administration of méthylène blue in septic shock: Is it beneficial? In Vincent J-L (ed): "Yearbook of Intensive Care and Emergency Medicine." Berlin: Springer, 1994, pp 90100.
24. Galanos C, Freudenberg M, Reutter W: Galactosamineinduced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sei USA 76:5939-5943, 1979.
25. Libert C, Van Bladel S, Brouckaert P, Fiers W: The influence of modulating substances on tumor necrosis factor and interleukin-6 levels after injection of murine tumor necrosis factor or lipopolysaccharide in mice. J Immunother 10:227-235, 1991.
26. Wallach D, Holtmann H, Engelmann H, Nophar Y: Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 140:2994-2999, 1988.
27. Libert C, Brouckaert P, Fiers W: Protection by oc,-acid glycoprotein against tumor necrosis factor-induced lethality. J Exp Med 180:1571-1575, 1994.
28. McNamara PJ, Brouwer KR, Gillespie MM: Autocoid binding to serum proteins. Interaction of platelet-activating factor (PAR with human serum alpha-1-acid glycoprotein (AAG). Biochem Pharmacol 35:621-624,1986.
29. Libert C, Van Molle W, Brouckaert P, Fiers W: Plateletactivating factor is a mediator in tumor necrosis factor/ galactosamine-induced lethality. J Inflammation 46: 139-143, 1996.
30. Libert C, Van Molle W, Brouckaert P, Fiers W: a1Antitrypsin inhibits the lethal response to tumor necrosis factor in mice. J Immunol 157:in press, 1996.
31. Bussolino F, Camussi G: Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties. Eur J Biochem 229:327-337, 1995.